ROLL study: Ranibizumab to aflibercept treatment change yields stable visual acuity results

MIAMI — Vision remained stable in patients whose treatment was changed from ranibizumab to aflibercept, but vascularized pigment epithelial detachments continue to be difficult to treat, a researcher reporting 6-month results of the ROLL study said here. The ROLL trial was initiated when the HiPED trial — an investigator-sponsored trial studying 2 mg Lucentis (ranibizumab, Genentech) in patients with neovascular age-related macular degeneration with recalcitrant fibrovascular pigment epithelial detachment (PED) — was terminated early because the 2 mg dose was no longer available.

Full Story →